276 related articles for article (PubMed ID: 24804545)
1. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
[TBL] [Abstract][Full Text] [Related]
2. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
Wang T; Lee K; Rehman A; Daoud SS
Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036
[TBL] [Abstract][Full Text] [Related]
3. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
[TBL] [Abstract][Full Text] [Related]
5. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
[TBL] [Abstract][Full Text] [Related]
6. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
Orue A; Chavez V; Strasberg-Rieber M; Rieber M
BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
[TBL] [Abstract][Full Text] [Related]
8. PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc.
Farhadi E; Safa M; Sharifi AM; Bashash D
Anticancer Drugs; 2017 Jan; 28(1):51-58. PubMed ID: 27548348
[TBL] [Abstract][Full Text] [Related]
9. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
[TBL] [Abstract][Full Text] [Related]
10. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins.
Rökaeus N; Klein G; Wiman KG; Szekely L; Mattsson K
Oncogene; 2007 Feb; 26(7):982-92. PubMed ID: 16909106
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
Wiman KG
Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
[TBL] [Abstract][Full Text] [Related]
12. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.
Rökaeus N; Shen J; Eckhardt I; Bykov VJ; Wiman KG; Wilhelm MT
Oncogene; 2010 Dec; 29(49):6442-51. PubMed ID: 20818419
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
14. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
15. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.
Cory AH; Chen J; Cory JG
Anticancer Res; 2006; 26(2A):1289-95. PubMed ID: 16619536
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells.
Messina RL; Sanfilippo M; Vella V; Pandini G; Vigneri P; Nicolosi ML; Gianì F; Vigneri R; Frasca F
Int J Cancer; 2012 May; 130(10):2259-70. PubMed ID: 21647879
[TBL] [Abstract][Full Text] [Related]
17. GADD45a physically and functionally interacts with TET1.
Kienhöfer S; Musheev MU; Stapf U; Helm M; Schomacher L; Niehrs C; Schäfer A
Differentiation; 2015; 90(1-3):59-68. PubMed ID: 26546041
[TBL] [Abstract][Full Text] [Related]
18. Antitumor Effects of PRIMA-1 and PRIMA-1
Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
Cells; 2021 Jan; 10(1):. PubMed ID: 33430525
[TBL] [Abstract][Full Text] [Related]
19. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
[TBL] [Abstract][Full Text] [Related]
20. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
Saha MN; Jiang H; Yang Y; Reece D; Chang H
Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
